FLGT vs. CSTL, CELC, CDNA, VRDN, SERA, BDSX, BNR, PSNL, RNLX, and VCYT
Should you be buying Fulgent Genetics stock or one of its competitors? The main competitors of Fulgent Genetics include Castle Biosciences (CSTL), Celcuity (CELC), CareDx (CDNA), Viridian Therapeutics (VRDN), Sera Prognostics (SERA), Biodesix (BDSX), Burning Rock Biotech (BNR), Personalis (PSNL), Renalytix (RNLX), and Veracyte (VCYT). These companies are all part of the "medical laboratories" industry.
Castle Biosciences (NASDAQ:CSTL) and Fulgent Genetics (NASDAQ:FLGT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, media sentiment, valuation, community ranking, risk and earnings.
Castle Biosciences has a beta of 0.93, suggesting that its share price is 7% less volatile than the S&P 500. Comparatively, Fulgent Genetics has a beta of 1.43, suggesting that its share price is 43% more volatile than the S&P 500.
In the previous week, Castle Biosciences had 7 more articles in the media than Fulgent Genetics. MarketBeat recorded 11 mentions for Castle Biosciences and 4 mentions for Fulgent Genetics. Fulgent Genetics' average media sentiment score of 0.72 beat Castle Biosciences' score of 0.22 indicating that Castle Biosciences is being referred to more favorably in the media.
Castle Biosciences has higher earnings, but lower revenue than Fulgent Genetics. Castle Biosciences is trading at a lower price-to-earnings ratio than Fulgent Genetics, indicating that it is currently the more affordable of the two stocks.
Castle Biosciences presently has a consensus target price of $31.57, indicating a potential upside of 29.66%. Fulgent Genetics has a consensus target price of $30.00, indicating a potential upside of 35.14%. Given Castle Biosciences' higher possible upside, analysts clearly believe Fulgent Genetics is more favorable than Castle Biosciences.
Castle Biosciences has a net margin of -12.28% compared to Castle Biosciences' net margin of -57.72%. Castle Biosciences' return on equity of -2.92% beat Fulgent Genetics' return on equity.
Fulgent Genetics received 163 more outperform votes than Castle Biosciences when rated by MarketBeat users. However, 62.31% of users gave Castle Biosciences an outperform vote while only 60.70% of users gave Fulgent Genetics an outperform vote.
92.6% of Castle Biosciences shares are held by institutional investors. Comparatively, 48.1% of Fulgent Genetics shares are held by institutional investors. 7.2% of Castle Biosciences shares are held by company insiders. Comparatively, 32.7% of Fulgent Genetics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Castle Biosciences beats Fulgent Genetics on 10 of the 18 factors compared between the two stocks.
Get Fulgent Genetics News Delivered to You Automatically
Sign up to receive the latest news and ratings for FLGT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FLGT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fulgent Genetics Competitors List
Related Companies and Tools
